Targeting IL-13 as a Host-Directed Therapy Against Ulcerative Colitis
The role of interleukin-13 in mediating ulcerative colitis remains under scrutiny. Compelling evidence from both man and mouse suggests that IL-13 not only contributes to the pathology associated with disease but is also involved in mediating the inflammatory response. These studies have led to the...
Main Author: | J. Claire Hoving |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-11-01
|
Series: | Frontiers in Cellular and Infection Microbiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fcimb.2018.00395/full |
Similar Items
-
Ulcerative colitis: Al-gassim experience
by: Contractor Qais, et al.
Published: (2004-01-01) -
Enteric infections complicating ulcerative colitis
by: Dejan Micic, et al.
Published: (2018-07-01) -
New developments in ulcerative colitis: latest evidence on management, treatment, and maintenance
by: Kartikeya Tripathi, et al.
Published: (2019-04-01) -
Ulcerative Colitis and Neopterin: Related?
by: Beşir Kesici, et al.
Published: (2019-04-01) -
Update on the Management of Ulcerative Colitis
by: Nasser Ebrahimi Daryani, et al.
Published: (2012-06-01)